Story
Zealand Pharma Stock Slides After Jefferies Downgrade on Survodutide Concerns
Summary
The Danish biotech firm's shares fell after Jefferies cut its rating and slashed its price target, citing a lack of near-term catalysts and lingering doubts over the clinical profile of its key drug candidate, survodutide.
Shares of Zealand Pharma fell 2.0% on Tuesday after analysts at Jefferies downgraded the stock, citing a lack of significant near-term catalysts and persistent concerns over the clinical data for its key obesity drug candidate, survodutide.
Jefferies Cites Lack of Catalysts
In a note to clients, Jefferies downgraded Zealand Pharma to Hold from a previous Buy rating. The firm also significantly reduced its price target on the stock to DKK 320 from DKK 505, a cut of approximately 37%.
The downgrade was driven by two primary factors:
- A perceived absence of major value-driving events for the company in the second half of 2026.
- A reduced probability of success for survodutide, which was lowered to 40% from 60%.
Survodutide Under Scrutiny
AdSurvodutide, a glucagon/GLP-1 dual agonist being co-developed with Boehringer Ingelheim, has faced increasing analyst scrutiny. The concerns stem from Phase III data presented in June at the American Diabetes Association meeting, which raised questions about the drug's tolerability profile.
Jefferies' action follows a similar move last month by Wolfe Research, which also removed its Outperform rating. Analysts have highlighted a placebo-adjusted patient discontinuation rate for survodutide that was notably higher than those observed in trials for rival therapies from market leaders Novo Nordisk and Eli Lilly.
Market Outlook
With no company-specific news or earnings released Tuesday, the Jefferies downgrade was the clear driver of the stock's decline. The move adds to a broader risk-off sentiment in the market, with Copenhagen's OMXC25 index and major U.S. indexes also trading lower.
Multiple investment banks, including Jefferies and UBS, have suggested that a significant positive inflection point for Zealand Pharma's stock is unlikely before 2027. This shifts the near-term focus to the company's pipeline, particularly petrelintide, an amylin analog being advanced into Phase 3 trials with Roche.
Read next
More on Stocks
Bank of England Outlines Decade-Long Plan to Shrink Balance Sheet by £368 Billion
The Bank of England has detailed a long-term strategy to reduce its government bond holdings by £368 billion by 2034, a move that will systematically tighten financial conditions and poses a long-term headwind for risk assets like Bitcoin.
Solana (SOL) Surges Past $112 on $85M ETF Inflow and Massive Short Squeeze
Solana's native token, SOL, has broken through the $112 level, driven by substantial institutional inflows into the Bitwise Solana Staking ETF (BSOL) and a derivatives market short squeeze that liquidated over $36 million in bearish positions.
Tempus AI Rally Puts Spotlight on AI for Science Peer Deshi Technology
A recent surge in Tempus AI's stock is prompting investors to re-evaluate Hong Kong-listed Deshi Technology, which operates a similar AI for Science (AI4S) platform focused on medical data and model development.
Hedge Funds Flip to Bullish Yen Stance for First Time in 14 Months
Leveraged funds established a net long position in the Japanese yen for the first time since July 2025, according to CFTC data, a major sentiment shift that was immediately tested by central bank policy and renewed threats of currency intervention.